| PTLE 0.282 51.53% | SOXS 3.65 11.56% | MSPR 0.664 27.57% | SCNX 0.8182 15.35% | NVDA 198.69 -3.96% | SQQQ 13.79 6.16% | ORIS 0.1603 -0.12% | BYND 1.33 -4.32% | PFE 24.3 -1.46% | HTZ 6.73 36.23% | PLTR 190.74 -7.94% | TSLL 20.34 -10.16% | ETHA 24.28 -10.37% | ASST 1.25 -1.57% | IBIT 57.18 -5.53% | GRAB 5.785 -4.70% | INTC 37.03 -6.25% | PLUG 2.52 -8.36% | ONDS 5.96 -3.09% | OPEN 6.92 -8.83% | CHR 0.136 8.11% | FGL 0.5165 26.94% | DNN 2.74 -6.00% | TSLA 444.26 -5.15% | WTO 0.0497 -6.23% | CAPT 0.6615 31.77% | NFE 1.35 14.41% | SOXL 42.8 -11.90% | BITF 3.84 -6.57% | ETHD 5.26 20.92% | T 24.44 -0.37% | EPWK 0.0748 3.60% | F 12.79 -1.69% | SPY 675.24 -1.19% | SOFI 29.37 -4.11% | KVUE 15.97 -1.05% | ACHR 9.56 -8.25% | CIFR 22.51 -1.10% | QQQ 619.25 -2.03% | HIMS 42.79 -3.60% | GPUS 0.3494 -7.03% | TQQQ 111.08 -6.12% | LQD 110.68 0.14% | BTBT 3.18 -7.02% | AAL 12.65 -5.17% | TZA 8.21 5.26% | BURU 0.29 -7.91% | NCLH 18.79 -15.28% | RGTI 35.18 -10.07% | BTG 4 -5.77%

Understanding Market Valuations: A Comparative Analysis

Chicago Atlantic BDC, Inc. (NASDAQ:LIEN) is showing promising growth potential. LIEN is trading at $10.10, but its discounted cash flow (DCF) valuation is $14.35. This results in a price percentage difference of 42.03%, suggesting a positive outlook and potential for price appreciation. LIEN's strong position among its peers highlights its growth prospects.

Cinemark Holdings, Inc. (NYSE:CNK) is another peer, trading at $30.64 with a DCF of $18.05. This results in a price percentage difference of -41.08%, indicating a less favorable outlook compared to its current market price. Despite being a well-known name in the entertainment industry, CNK faces challenges in aligning its market price with its valuation.

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) trades at $0.389 with a DCF of $0.3556, showing a price percentage difference of -8.57%. This smaller discrepancy suggests a closer alignment between its market price and valuation, though it still indicates a slightly negative outlook. VRPX's focus on pharmaceutical developments may influence its market performance.

Regis Corporation (NYSE:RGS) is trading at $22.65, but its DCF is only $1.95, resulting in a significant price percentage difference of -91.37%. This large gap suggests a highly pessimistic view from analysts, similar to RGC. RGS's market challenges are evident in its substantial discrepancy between market price and valuation.

Published on: July 5, 2025